Popular Trials
Behavioural Intervention
Cognitive Behavioral Therapy for Insomnia in Brain Tumor Patients
Recruiting1 awardPhase 2
Richmond, Virginia
This trial aims to study a type of therapy called Cognitive Behavioral Therapy for Insomnia (CBT-I) in individuals with primary brain tumors who also have insomnia. The study will look at how feasible it
Radiation
Radiation Therapy for Recurrent Brain Tumors
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial aims to find a safe schedule for using radiation to treat brain tumors (GBM) that have returned after initial radiation treatment. Participants in the trial will undergo re-irradiation planning where
Virus Therapy
DB107-RRV + DB107-FC for Brain Tumors
Recruiting1 awardPhase 2
Miami, Florida
This trial aims to see if a new combination treatment can reduce the size of a type of brain cancer called high-grade glioma in patients with recurrent or progressive disease, whether the tumor can be surgically
Popular Filters
Trials for Glioblastoma Patients
Alkylating agents
Mycophenolate Mofetil + Standard Care for Glioblastoma
Recruiting2 awardsPhase 1
Chicago, Illinois
This trial tests if combining mycophenolate mofetil with temozolomide and radiation can better treat glioblastoma, an aggressive brain cancer. Mycophenolate mofetil may help chemotherapy work better by making cancer cells easier to kill. Temozolomide is a standard chemotherapeutic drug for glioblastoma, often combined with radiotherapy to improve patient survival.
Kinase Inhibitor
Dabrafenib + Trametinib for Brain Tumors
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
Molecular Profiling
Molecular Profiling for Brain Tumor
Recruiting1 award9 criteria
San Diego, California
This trial will test a new treatment approach for children with High-grade gliomas HGG that is based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500 gene panel), and RNA-Seq.
Trials for GBM Patients
Alkylating agents
Mycophenolate Mofetil + Standard Care for Glioblastoma
Recruiting2 awardsPhase 1
Chicago, Illinois
This trial tests if combining mycophenolate mofetil with temozolomide and radiation can better treat glioblastoma, an aggressive brain cancer. Mycophenolate mofetil may help chemotherapy work better by making cancer cells easier to kill. Temozolomide is a standard chemotherapeutic drug for glioblastoma, often combined with radiotherapy to improve patient survival.
Kinase Inhibitor
Dabrafenib + Trametinib for Brain Tumors
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
Molecular Profiling
Molecular Profiling for Brain Tumor
Recruiting1 award9 criteria
San Diego, California
This trial will test a new treatment approach for children with High-grade gliomas HGG that is based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500 gene panel), and RNA-Seq.
Trials for IDH Positive Patients
Radiation Therapy
Pulsed Radiotherapy for Brain Cancer
Recruiting1 award9 criteria
Saint Louis, Missouri
This trial studies the side effects of a new method of giving radiation in small, timed doses, in patients with certain types of brain tumors who have had earlier treatments. This approach may be more effective and less harmful.
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial tests a combination of a vitamin A derivative and an immune-boosting drug in patients with recurring brain tumors. The treatment aims to normalize cancer cell behavior and enhance the immune system's ability to fight the tumor.
PARP Inhibitor
PARP Inhibitor + Temozolomide for Brain Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial studies the safety and best dose of BGB-290 and temozolomide in treating young people with a specific type of brain tumor. BGB-290 blocks enzymes needed for tumor growth, while temozolomide kills or stops cancer cells from growing. The goal is to find out if this combination works better for these patients.
Trials With No Placebo
Radiation Therapy
Pulsed Radiotherapy for Brain Cancer
Recruiting1 award9 criteria
Saint Louis, Missouri
This trial studies the side effects of a new method of giving radiation in small, timed doses, in patients with certain types of brain tumors who have had earlier treatments. This approach may be more effective and less harmful.
PD-1 Inhibitor
ATRA + PD-1 Inhibitor for Brain Tumor
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial tests a combination of a vitamin A derivative and an immune-boosting drug in patients with recurring brain tumors. The treatment aims to normalize cancer cell behavior and enhance the immune system's ability to fight the tumor.
Alkylating agents
Mycophenolate Mofetil + Standard Care for Glioblastoma
Recruiting2 awardsPhase 1
Chicago, Illinois
This trial tests if combining mycophenolate mofetil with temozolomide and radiation can better treat glioblastoma, an aggressive brain cancer. Mycophenolate mofetil may help chemotherapy work better by making cancer cells easier to kill. Temozolomide is a standard chemotherapeutic drug for glioblastoma, often combined with radiotherapy to improve patient survival.
Kinase Inhibitor
Dabrafenib + Trametinib for Brain Tumors
Recruiting3 awardsPhase 4
Phoenix, Arizona
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.